Skip to main content
VulnerabilityPublished

CVE-2025-61940: NMIS/BioDose V22.02 and previous versions rely on a common SQL Server user account to access data in

Source GCVE Database

0
Compare
Authoritative record:CVE-2025-61940· High 8.7

Not known to be exploited · CVSS 8.7 High.

Data as of 22 Nov 2026, 02:48 UTC

CVSS 4.0 base score
8.7High
How severe the flaw is on the 0–10 CVSS scale.
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:L/SC:N/SI:N/SA:N

Exploitation evidence

  1. Disclosed: evidence found.

    CVE published 2 Dec 2025

  2. Detectable: no evidence on record.

    No public nuclei template indexed

  3. Weaponized: no evidence on record.

    No public exploit code indexed in Metasploit or Exploit-DB

  4. Exploited in the wild: no evidence on record.

    Not in CISA KEV and no source reports exploitation

  5. Observed by OffSeq Mirage: no evidence on record.

    No attack traffic recorded by OffSeq Mirage sensors

A missing step is not evidence of safety. Sources: cve.org (opens in a new tab), the Metasploit, Exploit-DB and nuclei-templates index as of 21 Nov 2026.

What to do

AI-suggested

Upgrade to the latest version of NMIS/BioDose that supports Windows user authentication for the database connection to enforce per-user access controls. Until then, restrict access to the client application and database server to trusted users only.

Description

NMIS/BioDose versions 22.02 and earlier use a shared SQL Server user account for database access. While client software enforces user authentication, the database connection itself always uses this common account, potentially allowing broader access than intended. The latest version adds an option for Windows user authentication to restrict database access per user.

References

Community reviews

Loading reviews…